According to the latest research by InsightAce Analytic, the global Cell and Gene Therapy Drug Delivery Devices market is valued at US$ 116.29 Thousands in 2021, and it is expected to grow with a CAGR of 15.96% during a forecast period of 2022-2030.The demand for cell and gene therapy drug delivery devices market is enhancing as there is an increase in the number of patients suffering from cancer, diabetes, and other chronic diseases. Therefore, there is a high need of developing affordable and cost-effective cell and gene therapies. Cell and gene therapy is a clinical procedure of modifying genetic material for the treatment of various diseases. Drug Delivery devices have the capacity to perform multiple functions with the highest degree of smartness. Cell and Gene Therapy Drug Delivery Devices are beneficial in the treatment of respiratory diseases, diabetes, and other cardiovascular disorders.
Spreading awareness regarding the benefits of cell and gene therapy drug delivery devices is expected to propel the product demand. Furthermore, fast adoption of advanced technologies, an invention of new devices according to patient’s requirements, increasing government initiatives for research and development of new therapies and devices, high prevalence of chronic diseases, rising number of clinical trials, and creation of smartphone applications will also help to upscale this market. However, the high cost of manufacturing systems, lack of standard therapy protocols, complex procedures, and shortage of skilled professionals are limiting the growth of this market.
The cell and gene therapy drug delivery devices market can be segmented on the basis of products, Commercialized Drugs, and Regions. On the basis of products, the market can be sub-divided into Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags. On the basis of Commercialized Drugs, the market is sub-segmented into Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, and Strimvelis. Commercialized Drugs segment is expected to dominate this market, as these drugs are modified and prepared according to patient’s requirements. In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Out of these regions, North America is expected to dominate the market over the forecast period (2019-2030).
Some of the key players of Cell and Gene Therapy Drug Delivery Devices Market are Bausch & Lomb Incorporated., Amgen Inc., Becton, Dickinson and Company, Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC., Bluebird bio, Inc., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., Kolon TissueGene, Inc., Vericel Corporation, uniQure N.V., and list of other prominent players.
